OncoMatch/Clinical Trials/NCT06726148
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Is NCT06726148 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including ECI830 and ribociclib for advanced hr+/her2- breast cancer.
Treatment: ECI830 · ribociclib · fulvestrant — Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Tumor Agnostic
Biomarker criteria
Required: CCNE1 amplification
Required: HER2 (ERBB2) wild-type
Disease stage
Required: Stage III, IV
Metastatic disease required
locally advanced or metastatic cancer; unresectable/metastatic disease
Prior therapy
Must have received: hormonal therapy — metastatic
disease progression on or following at least one line of hormone-based therapy in combination with a CDK4/6i and at least one additional line of systemic therapy for metastatic disease
Must have received: CDK4/6 inhibitor — metastatic
disease progression on or following at least one line of hormone-based therapy in combination with a CDK4/6i
Cannot have received: CDK2 inhibitor
Previous treatment with a CDK2 inhibitor at any time
Lab requirements
Blood counts
no inadequate bone marrow function with out-of-range laboratory values
Kidney function
no inadequate organ function with out-of-range laboratory values
Liver function
no inadequate organ function with out-of-range laboratory values
Cardiac function
no clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality including MI, CABG, long QT syndrome, or risk factors for TdP
Patients with inadequate bone marrow and/or organ functions with out-of-range laboratory values. Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality including MI, CABG, long QT syndrome, or risk factors for TdP.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California LA · Los Angeles, California
- Florida Cancer Specialists · Fort Myers, Florida
- Dana Farber Cancer Institute · Boston, Massachusetts
- WA Uni School Of Med · St Louis, Missouri
- Memorial Sloan Kettering · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify